Trial Profile
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Rigel Pharmaceuticals
- 04 Feb 2024 This trial has been Discontinued in Italy, according to European Clinical Trials Database record.
- 24 Sep 2023 This trial has been completed in Spain.
- 18 Feb 2023 This trial has been completed in Czech Republic (End Date: 19 Dec 2022) according to European Clinical Trials Database record.